In the first-in-human trial by Zhou et al., which consisted of seven patients (NSCLC: n = 3; esophageal cancer: n = 4), patients with NSCLC with high PD-L1 expression had higher tumor uptake than those with low expression (SUVmax: 3.29 vs. 2.22). Here, CD274 is linked to neoplasm.